FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089348501> ?p ?o ?g. }

• W3089348501 endingPage "226" @default.
• W3089348501 startingPage "217" @default.
• W3089348501 abstract "Introduction Prostate cancer progresses, despite androgen-deprivation therapy, the backbone of its treatment. This progression is mainly related to the androgen receptor (AR)-related mechanisms of resistance, and, several AR-targeted therapies have demonstrated benefit in metastatic and nonmetastatic disease. Apalutamide is a third-generation AR-targeted therapy which competitively blocks the AR and prevents AR dimerization, nuclear internalization, thereby avoiding cancer progression. Early studies have demonstrated that apalutamide was safe and demonstrated clinical benefit. Phase II and phase III studies had confirmed preliminary results of clinical benefit with apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and in metastatic hormone-sensitive prostate cancer (mHSPC).Areas covered Herein, the authors discuss the development of apalutamide, from its discovery and early studies to phase III trials. They also examine new perspectives and biomarkers that may help oncologists to make decisions in patients taking apalutamide. Studies evaluating apalutamide in other settings and in combination with other therapies are also debated.Expert opinion Apalutamide has become a relevant therapy for patients with nmCRPC and mHSPC for its benefit in delaying metastasis in addition to its improvement of overall survival, without compromising the quality of life. Apalutamide should be considered as a standard-of-care for patients with nmCRPC and patients with mHSPC." @default.
• W3089348501 created "2020-10-08" @default.
• W3089348501 creator A5003722043 @default.
• W3089348501 creator A5011495504 @default.
• W3089348501 creator A5017052911 @default.
• W3089348501 creator A5069538784 @default.
• W3089348501 creator A5084509050 @default.
• W3089348501 date "2020-10-12" @default.
• W3089348501 modified "2023-10-17" @default.
• W3089348501 title "The development of apalutamide for the treatment of prostate cancer" @default.
• W3089348501 cites W1964891491 @default.
• W3089348501 cites W1969498141 @default.
• W3089348501 cites W1972298018 @default.
• W3089348501 cites W2050602600 @default.
• W3089348501 cites W2077815818 @default.
• W3089348501 cites W2084637523 @default.
• W3089348501 cites W2089518544 @default.
• W3089348501 cites W2105129152 @default.
• W3089348501 cites W2110534364 @default.
• W3089348501 cites W2119504728 @default.
• W3089348501 cites W2132140718 @default.
• W3089348501 cites W2137467802 @default.
• W3089348501 cites W2147166694 @default.
• W3089348501 cites W2148643283 @default.
• W3089348501 cites W2150865892 @default.
• W3089348501 cites W2156923287 @default.
• W3089348501 cites W2160463964 @default.
• W3089348501 cites W2166918329 @default.
• W3089348501 cites W2214621962 @default.
• W3089348501 cites W2295538098 @default.
• W3089348501 cites W2346677152 @default.
• W3089348501 cites W2418110744 @default.
• W3089348501 cites W2419426348 @default.
• W3089348501 cites W2588126825 @default.
• W3089348501 cites W2613162682 @default.
• W3089348501 cites W2620746860 @default.
• W3089348501 cites W2620798309 @default.
• W3089348501 cites W2626230492 @default.
• W3089348501 cites W2766627726 @default.
• W3089348501 cites W2775455154 @default.
• W3089348501 cites W2791535250 @default.
• W3089348501 cites W2792086148 @default.
• W3089348501 cites W2802540286 @default.
• W3089348501 cites W2805553258 @default.
• W3089348501 cites W2810806599 @default.
• W3089348501 cites W2891576771 @default.
• W3089348501 cites W2904591950 @default.
• W3089348501 cites W2911490798 @default.
• W3089348501 cites W2913767564 @default.
• W3089348501 cites W2917593000 @default.
• W3089348501 cites W2928270062 @default.
• W3089348501 cites W2945522282 @default.
• W3089348501 cites W2947014957 @default.
• W3089348501 cites W2947893479 @default.
• W3089348501 cites W2948919866 @default.
• W3089348501 cites W2963794755 @default.
• W3089348501 cites W2973096717 @default.
• W3089348501 cites W2975006240 @default.
• W3089348501 cites W2976281902 @default.
• W3089348501 cites W2996439339 @default.
• W3089348501 cites W3007011398 @default.
• W3089348501 cites W3030001291 @default.
• W3089348501 cites W3031020438 @default.
• W3089348501 cites W3032259164 @default.
• W3089348501 cites W3084238852 @default.
• W3089348501 doi "https://doi.org/10.1080/17460441.2021.1829588" @default.
• W3089348501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33003959" @default.
• W3089348501 hasPublicationYear "2020" @default.
• W3089348501 type Work @default.
• W3089348501 sameAs 3089348501 @default.
• W3089348501 citedByCount "5" @default.
• W3089348501 countsByYear W30893485012022 @default.
• W3089348501 countsByYear W30893485012023 @default.
• W3089348501 crossrefType "journal-article" @default.
• W3089348501 hasAuthorship W3089348501A5003722043 @default.
• W3089348501 hasAuthorship W3089348501A5011495504 @default.
• W3089348501 hasAuthorship W3089348501A5017052911 @default.
• W3089348501 hasAuthorship W3089348501A5069538784 @default.
• W3089348501 hasAuthorship W3089348501A5084509050 @default.
• W3089348501 hasConcept C121608353 @default.
• W3089348501 hasConcept C126322002 @default.
• W3089348501 hasConcept C143998085 @default.
• W3089348501 hasConcept C2779322244 @default.
• W3089348501 hasConcept C2780192828 @default.
• W3089348501 hasConcept C535046627 @default.
• W3089348501 hasConcept C61367390 @default.
• W3089348501 hasConcept C71924100 @default.
• W3089348501 hasConceptScore W3089348501C121608353 @default.
• W3089348501 hasConceptScore W3089348501C126322002 @default.
• W3089348501 hasConceptScore W3089348501C143998085 @default.
• W3089348501 hasConceptScore W3089348501C2779322244 @default.
• W3089348501 hasConceptScore W3089348501C2780192828 @default.
• W3089348501 hasConceptScore W3089348501C535046627 @default.
• W3089348501 hasConceptScore W3089348501C61367390 @default.
• W3089348501 hasConceptScore W3089348501C71924100 @default.
• W3089348501 hasIssue "3" @default.
• W3089348501 hasLocation W30893485011 @default.
• W3089348501 hasOpenAccess W3089348501 @default.

• next